Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0000950170-23-015824

Options or other derivatives

  • Chief Legal Officer acquired 127,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Oltmans Curtis Gale Chief Legal Officer 2023-04-26 Grant or award · Stock Option (right to buy) +127,500 127,500 D
Loading xslF345X04/ownership.xml…